JP2004509952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509952A5 JP2004509952A5 JP2002531106A JP2002531106A JP2004509952A5 JP 2004509952 A5 JP2004509952 A5 JP 2004509952A5 JP 2002531106 A JP2002531106 A JP 2002531106A JP 2002531106 A JP2002531106 A JP 2002531106A JP 2004509952 A5 JP2004509952 A5 JP 2004509952A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- morpholin
- acetamide
- dichlorobenzyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 149
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 141
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 103
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 50
- -1 NR13 Chemical compound 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 26
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 8
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- MKCWTWOIIWRROF-UHFFFAOYSA-N 1-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzotriazole-5-carboxylic acid Chemical compound OC(=O)c1ccc2n(CC(=O)NCC3CN(Cc4ccc(Cl)c(Cl)c4)CCO3)nnc2c1 MKCWTWOIIWRROF-UHFFFAOYSA-N 0.000 description 1
- JYFNSZDTDYRIHG-UHFFFAOYSA-N 2-(2,5-dichlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound ClC1=CC=C(Cl)C(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 JYFNSZDTDYRIHG-UHFFFAOYSA-N 0.000 description 1
- JYJSYZYBAVZUHV-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2C(=CC=CC=2Cl)Cl)OCC1 JYJSYZYBAVZUHV-UHFFFAOYSA-N 0.000 description 1
- LZKQBIBTGJUICE-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2C(=CC=CC=2)Cl)OCC1 LZKQBIBTGJUICE-UHFFFAOYSA-N 0.000 description 1
- UIZQMDGRYJFZQK-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2C=C(Cl)C(Cl)=CC=2)OCC1 UIZQMDGRYJFZQK-UHFFFAOYSA-N 0.000 description 1
- LDDDEDCDPPPQFT-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound ClC1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 LDDDEDCDPPPQFT-UHFFFAOYSA-N 0.000 description 1
- KQJLAVQBOMJGFC-UHFFFAOYSA-N 2-(4-bromo-3,5-dimethylpyrazol-1-yl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound CC1=C(Br)C(C)=NN1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 KQJLAVQBOMJGFC-UHFFFAOYSA-N 0.000 description 1
- JHMXPUCRTAYCDZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound C1=CC(Cl)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 JHMXPUCRTAYCDZ-UHFFFAOYSA-N 0.000 description 1
- UQVDLUQACOPECV-UGNFMNBCSA-N 2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]-n-[[(2s)-4-(1-phenylethyl)morpholin-2-yl]methyl]acetamide Chemical compound C([C@@H]1OCCN(C1)C(C)C=1C=CC=CC=1)NC(=O)CC(=C(O1)C)N=C1C1=CC=C(F)C=C1 UQVDLUQACOPECV-UGNFMNBCSA-N 0.000 description 1
- WISMQAZNLJWJDU-NRFANRHFSA-N 2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]-n-[[(2s)-4-[2-(4-fluorophenyl)-2-oxoethyl]morpholin-2-yl]methyl]acetamide Chemical compound C([C@@H](OCC1)CNC(=O)CC=2N=C(OC=2C)C=2C=CC(F)=CC=2)N1CC(=O)C1=CC=C(F)C=C1 WISMQAZNLJWJDU-NRFANRHFSA-N 0.000 description 1
- OUXCRTKKJLVYBY-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]acetamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 OUXCRTKKJLVYBY-UHFFFAOYSA-N 0.000 description 1
- ANCDHBXLDURTHN-UHFFFAOYSA-N 2-phenoxypropanamide Chemical compound NC(=O)C(C)OC1=CC=CC=C1 ANCDHBXLDURTHN-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- NHOITSTWCDUYAQ-QFIPXVFZSA-N 3-[2-[[(2s)-4-[(3-chlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-cyclopropylbenzamide Chemical compound ClC1=CC=CC(CN2C[C@H](CNC(=O)CC=3C=C(C=CC=3)C(=O)NC3CC3)OCC2)=C1 NHOITSTWCDUYAQ-QFIPXVFZSA-N 0.000 description 1
- ROBASCRROMVVND-SFHVURJKSA-N 3-[2-[[(2s)-4-[(5-chlorothiophen-2-yl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-cyclopropylbenzamide Chemical compound S1C(Cl)=CC=C1CN1C[C@H](CNC(=O)CC=2C=C(C=CC=2)C(=O)NC2CC2)OCC1 ROBASCRROMVVND-SFHVURJKSA-N 0.000 description 1
- FTTPPVDVQPABRK-UHFFFAOYSA-N 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 FTTPPVDVQPABRK-UHFFFAOYSA-N 0.000 description 1
- OJQGJGGPRSOVAM-UHFFFAOYSA-N 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 OJQGJGGPRSOVAM-UHFFFAOYSA-N 0.000 description 1
- LJJGPPAFVHTUBZ-UHFFFAOYSA-N 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 LJJGPPAFVHTUBZ-UHFFFAOYSA-N 0.000 description 1
- HWXSNLXRQOVRFJ-UHFFFAOYSA-N 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzotriazole-5-carboxylic acid Chemical compound C12=CC(C(=O)O)=CC=C2N=NN1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 HWXSNLXRQOVRFJ-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- CPTHFDQFZLWHSN-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 CPTHFDQFZLWHSN-UHFFFAOYSA-N 0.000 description 1
- YIMJPSBXMJBMCH-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-ethylbenzamide Chemical compound C1=CC(C(=O)NCC)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 YIMJPSBXMJBMCH-UHFFFAOYSA-N 0.000 description 1
- RBCYAHOMYPCVHJ-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 RBCYAHOMYPCVHJ-UHFFFAOYSA-N 0.000 description 1
- UVGVPEKRWGKGKZ-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-n-propan-2-ylbenzamide Chemical compound C1=CC(C(=O)NC(C)C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 UVGVPEKRWGKGKZ-UHFFFAOYSA-N 0.000 description 1
- QAAZDCGSSWACNU-UHFFFAOYSA-N 4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 QAAZDCGSSWACNU-UHFFFAOYSA-N 0.000 description 1
- XJCCVBPRDUAFBK-NRFANRHFSA-N 4-[4-[2-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]-5-methyl-1,3-oxazol-2-yl]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C1=NC(CC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C(C)O1 XJCCVBPRDUAFBK-NRFANRHFSA-N 0.000 description 1
- PTUBNTVRWLDJBP-CRAIPNDOSA-N ClC=1C=C(CN2C[C@H](OC[C@H]2C)CNC(CC2=CC=CC=C2)=O)C=CC=1Cl Chemical compound ClC=1C=C(CN2C[C@H](OC[C@H]2C)CNC(CC2=CC=CC=C2)=O)C=CC=1Cl PTUBNTVRWLDJBP-CRAIPNDOSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CODAIKLZEIPJNA-UHFFFAOYSA-N N-(5-phenyltetrazol-2-yl)acetamide Chemical compound C(C)(=O)NN1N=C(N=N1)C1=CC=CC=C1 CODAIKLZEIPJNA-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HFUNQLVTMBETML-UHFFFAOYSA-N methyl 2-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzotriazole-5-carboxylate Chemical compound N1=C2C=C(C(=O)OC)C=CC2=NN1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 HFUNQLVTMBETML-UHFFFAOYSA-N 0.000 description 1
- BTLXBJBBTNKZOW-UHFFFAOYSA-N methyl 3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]benzoate Chemical compound COC(=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 BTLXBJBBTNKZOW-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- PIZQTSMNGFLAOU-UHFFFAOYSA-N n-[3-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]phenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 PIZQTSMNGFLAOU-UHFFFAOYSA-N 0.000 description 1
- IXFWJWZFPVVHBE-UHFFFAOYSA-N n-[4-[2-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]phenyl]-2-methylpropanamide Chemical compound C1=CC(NC(=O)C(C)C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 IXFWJWZFPVVHBE-UHFFFAOYSA-N 0.000 description 1
- MIJQXFRSAOOOTI-QGZVFWFLSA-N n-[[(2r)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methylsulfonylphenyl)acetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CC(=O)NC[C@H]1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 MIJQXFRSAOOOTI-QGZVFWFLSA-N 0.000 description 1
- FGUIUYGIZLOOHE-LJQANCHMSA-N n-[[(2r)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetamide Chemical compound C([C@H](OCC1)CNC(=O)CC=2N=C(OC=2C)C=2C=CC=CC=2)N1CC1=CC=C(Cl)C(Cl)=C1 FGUIUYGIZLOOHE-LJQANCHMSA-N 0.000 description 1
- VOSAXWZFOHNAKO-MRXNPFEDSA-N n-[[(2r)-4-[(5-chlorothiophen-2-yl)methyl]morpholin-2-yl]methyl]-2-[3-(methanesulfonamido)phenyl]acetamide Chemical compound CS(=O)(=O)NC1=CC=CC(CC(=O)NC[C@H]2OCCN(CC=3SC(Cl)=CC=3)C2)=C1 VOSAXWZFOHNAKO-MRXNPFEDSA-N 0.000 description 1
- PTUBNTVRWLDJBP-MAUKXSAKSA-N n-[[(2r,5s)-4-[(3,4-dichlorophenyl)methyl]-5-methylmorpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C([C@H]1OC[C@@H](N(C1)CC=1C=C(Cl)C(Cl)=CC=1)C)NC(=O)CC1=CC=CC=C1 PTUBNTVRWLDJBP-MAUKXSAKSA-N 0.000 description 1
- LHEXVCZVAZHCCT-IBGZPJMESA-N n-[[(2s)-4-(2,1,3-benzoxadiazol-5-ylmethyl)morpholin-2-yl]methyl]-2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]acetamide Chemical compound N=1C(CC(=O)NC[C@@H]2OCCN(CC3=CC4=NON=C4C=C3)C2)=C(C)OC=1C1=CC=C(F)C=C1 LHEXVCZVAZHCCT-IBGZPJMESA-N 0.000 description 1
- MIJQXFRSAOOOTI-KRWDZBQOSA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methylsulfonylphenyl)acetamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CC(=O)NC[C@@H]1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 MIJQXFRSAOOOTI-KRWDZBQOSA-N 0.000 description 1
- FGUIUYGIZLOOHE-IBGZPJMESA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetamide Chemical compound C([C@@H](OCC1)CNC(=O)CC=2N=C(OC=2C)C=2C=CC=CC=2)N1CC1=CC=C(Cl)C(Cl)=C1 FGUIUYGIZLOOHE-IBGZPJMESA-N 0.000 description 1
- IRPHGDKGHNCXIA-HNNXBMFYSA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-4-methylpentanamide Chemical compound C1CO[C@@H](CNC(=O)CCC(C)C)CN1CC1=CC=C(Cl)C(Cl)=C1 IRPHGDKGHNCXIA-HNNXBMFYSA-N 0.000 description 1
- STEXWNBVZFVLID-ZDUSSCGKSA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]cyclopropanecarboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C[C@H](CNC(=O)C2CC2)OCC1 STEXWNBVZFVLID-ZDUSSCGKSA-N 0.000 description 1
- DXUSLRXHNWADRT-AWEZNQCLSA-N n-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]pentanamide Chemical compound C1CO[C@@H](CNC(=O)CCCC)CN1CC1=CC=C(Cl)C(Cl)=C1 DXUSLRXHNWADRT-AWEZNQCLSA-N 0.000 description 1
- VOSAXWZFOHNAKO-INIZCTEOSA-N n-[[(2s)-4-[(5-chlorothiophen-2-yl)methyl]morpholin-2-yl]methyl]-2-[3-(methanesulfonamido)phenyl]acetamide Chemical compound CS(=O)(=O)NC1=CC=CC(CC(=O)NC[C@@H]2OCCN(CC=3SC(Cl)=CC=3)C2)=C1 VOSAXWZFOHNAKO-INIZCTEOSA-N 0.000 description 1
- MMUXUFDKBNTQRW-QFIPXVFZSA-N n-[[(2s)-4-[2-(3-chlorophenoxy)ethyl]morpholin-2-yl]methyl]-2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]acetamide Chemical compound C([C@@H](OCC1)CNC(=O)CC=2N=C(OC=2C)C=2C=CC(F)=CC=2)N1CCOC1=CC=CC(Cl)=C1 MMUXUFDKBNTQRW-QFIPXVFZSA-N 0.000 description 1
- IHTMDVDZFSXHBH-BEFAXECRSA-N n-[[(2s,5r)-4-[(2,5-dichlorophenyl)methyl]-5-methylmorpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C([C@@H]1OC[C@H](N(C1)CC=1C(=CC=C(Cl)C=1)Cl)C)NC(=O)CC1=CC=CC=C1 IHTMDVDZFSXHBH-BEFAXECRSA-N 0.000 description 1
- PTUBNTVRWLDJBP-QAPCUYQASA-N n-[[(2s,5r)-4-[(3,4-dichlorophenyl)methyl]-5-methylmorpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C([C@@H]1OC[C@H](N(C1)CC=1C=C(Cl)C(Cl)=CC=1)C)NC(=O)CC1=CC=CC=C1 PTUBNTVRWLDJBP-QAPCUYQASA-N 0.000 description 1
- KHRWSTKNTPHEIX-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(2,6-difluorophenyl)acetamide Chemical compound FC1=CC=CC(F)=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 KHRWSTKNTPHEIX-UHFFFAOYSA-N 0.000 description 1
- SASFTZBPEAQHTN-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(2-phenyl-1,3-thiazol-4-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2N=C(SC=2)C=2C=CC=CC=2)OCC1 SASFTZBPEAQHTN-UHFFFAOYSA-N 0.000 description 1
- FCLWTLISXFHQEU-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(3,4-difluorophenyl)acetamide Chemical compound C1=C(F)C(F)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 FCLWTLISXFHQEU-UHFFFAOYSA-N 0.000 description 1
- ROLSNQHXWUPMFL-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 ROLSNQHXWUPMFL-UHFFFAOYSA-N 0.000 description 1
- IZOYGZNMKXARJZ-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(3-nitrophenyl)acetamide Chemical compound [O-][N+](=O)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 IZOYGZNMKXARJZ-UHFFFAOYSA-N 0.000 description 1
- DNZXWUUNTDBKFN-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-fluoro-2-methylphenyl)acetamide Chemical compound CC1=CC(F)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 DNZXWUUNTDBKFN-UHFFFAOYSA-N 0.000 description 1
- QSVIELROKCBLGE-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 QSVIELROKCBLGE-UHFFFAOYSA-N 0.000 description 1
- FWZOQJCUPXLSIO-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 FWZOQJCUPXLSIO-UHFFFAOYSA-N 0.000 description 1
- GLLIZTBQMBJXFI-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 GLLIZTBQMBJXFI-UHFFFAOYSA-N 0.000 description 1
- KZFUBTRBLPLQIJ-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-methylsulfanylphenyl)acetamide Chemical compound C1=CC(SC)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 KZFUBTRBLPLQIJ-UHFFFAOYSA-N 0.000 description 1
- FRZLJHUTGANTLG-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(4-nitrophenyl)acetamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 FRZLJHUTGANTLG-UHFFFAOYSA-N 0.000 description 1
- GRDFSBFJZSAGAC-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methoxy-2-methyl-1h-indol-3-yl)acetamide Chemical compound C12=CC(OC)=CC=C2NC(C)=C1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 GRDFSBFJZSAGAC-UHFFFAOYSA-N 0.000 description 1
- USILSJUHUPHFFZ-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methyl-1-phenylpyrazol-4-yl)acetamide Chemical compound C1=NN(C=2C=CC=CC=2)C(C)=C1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 USILSJUHUPHFFZ-UHFFFAOYSA-N 0.000 description 1
- FGUIUYGIZLOOHE-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetamide Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 FGUIUYGIZLOOHE-UHFFFAOYSA-N 0.000 description 1
- XVWANSPPDJZSCG-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-(furan-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2OC=CC=2)OCC1 XVWANSPPDJZSCG-UHFFFAOYSA-N 0.000 description 1
- COIFKIVUCMELOL-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]acetamide Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1CC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 COIFKIVUCMELOL-UHFFFAOYSA-N 0.000 description 1
- XOUDBQNDBJIUDX-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-[3-[methyl(methylsulfonyl)amino]phenyl]acetamide Chemical compound CS(=O)(=O)N(C)C1=CC=CC(CC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 XOUDBQNDBJIUDX-UHFFFAOYSA-N 0.000 description 1
- AXAYMEOPQHXZBZ-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-[4-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 AXAYMEOPQHXZBZ-UHFFFAOYSA-N 0.000 description 1
- HMCGXXKIOWCREI-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC=2C=CC=CC=2)OCC1 HMCGXXKIOWCREI-UHFFFAOYSA-N 0.000 description 1
- ZMGHLJFRSADFNU-UHFFFAOYSA-N n-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-2-thiophen-3-ylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)CC2=CSC=C2)OCC1 ZMGHLJFRSADFNU-UHFFFAOYSA-N 0.000 description 1
- CVXRGDUVLQHQIF-UHFFFAOYSA-N n-[[4-[(3-fluorophenyl)methyl]morpholin-2-yl]methyl]-2-[4-(methanesulfonamido)phenyl]acetamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CC(=O)NCC1OCCN(CC=2C=C(F)C=CC=2)C1 CVXRGDUVLQHQIF-UHFFFAOYSA-N 0.000 description 1
- LZTXBUAOAXGSET-UHFFFAOYSA-N n-[[4-[3-(3,4-dichlorophenyl)propyl]morpholin-2-yl]methyl]-2-phenoxyacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CCCN1CC(CNC(=O)COC=2C=CC=CC=2)OCC1 LZTXBUAOAXGSET-UHFFFAOYSA-N 0.000 description 1
- PIGPZJQOGGOVGR-UHFFFAOYSA-N n-[[4-[3-(3,4-dichlorophenyl)propyl]morpholin-2-yl]methyl]-2-phenylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CCCN1CC(CNC(=O)CC=2C=CC=CC=2)OCC1 PIGPZJQOGGOVGR-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0023902.0 | 2000-09-29 | ||
| GB0023902A GB0023902D0 (en) | 2000-09-29 | 2000-09-29 | Therapeutically useful compounds |
| GB0107644A GB0107644D0 (en) | 2001-03-27 | 2001-03-27 | Therapeutically useful compounds |
| GB0107644.7 | 2001-03-27 | ||
| PCT/GB2001/004345 WO2002026722A1 (en) | 2000-09-29 | 2001-09-28 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004509952A JP2004509952A (ja) | 2004-04-02 |
| JP2004509952A5 true JP2004509952A5 (cg-RX-API-DMAC7.html) | 2008-11-13 |
| JP5089846B2 JP5089846B2 (ja) | 2012-12-05 |
Family
ID=26245078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002531106A Expired - Lifetime JP5089846B2 (ja) | 2000-09-29 | 2001-09-28 | 炎症性疾患を処置するためのモルホリン−アセトアミド誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US7101882B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1324990B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5089846B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20030031198A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1678594A (cg-RX-API-DMAC7.html) |
| AR (1) | AR035205A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2001290143A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0114323A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2423251A1 (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ20031195A3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2527688T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0302302A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL155093A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03002814A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20031442L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ525056A (cg-RX-API-DMAC7.html) |
| PL (1) | PL362711A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002026722A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0114323A (pt) * | 2000-09-29 | 2003-07-01 | Glaxo Group Ltd | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto |
| DE60108420T2 (de) * | 2000-11-28 | 2005-12-22 | Smithkline Beecham P.L.C., Brentford | Morpholinderivate als antagonisten an orexinrezeptoren |
| GB0207449D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
| GB0207443D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0208158D0 (en) * | 2002-03-28 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0207445D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0211759D0 (en) * | 2002-05-22 | 2002-07-03 | Glaxo Group Ltd | Novel compounds |
| GB0212357D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| GB0212355D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| PL1801108T3 (pl) * | 2004-09-08 | 2013-04-30 | Mitsubishi Tanabe Pharma Corp | Związki morfolinowe do leczenia stanów zapalnych |
| JP5281291B2 (ja) | 2005-01-10 | 2013-09-04 | グラクソ グループ リミテッド | 新規化合物 |
| AR053346A1 (es) | 2005-03-25 | 2007-05-02 | Glaxo Group Ltd | Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38 |
| UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| JP2009501792A (ja) * | 2005-07-21 | 2009-01-22 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体のモジュレーターとしてのｎ−ベンジル−モルホリン誘導体 |
| PE20071227A1 (es) | 2006-04-20 | 2008-02-18 | Glaxo Group Ltd | Compuestos derivados de indazol como moduladores del receptor de glucocorticoides |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| CN101506203B (zh) | 2006-08-24 | 2013-10-16 | 诺瓦提斯公司 | 治疗代谢病、心血管病和其他病症的作为硬脂酰辅酶a脱饱和酶(scd)抑制剂的2-(吡嗪-2-基)-噻唑和2-(1h-吡唑-3-基)-噻唑衍生物及相关化合物 |
| WO2008036715A1 (en) | 2006-09-22 | 2008-03-27 | Novartis Ag | Heterocyclic organic compounds |
| EP2121671A1 (en) | 2006-12-20 | 2009-11-25 | Novartis AG | 2-substituted 5-membered heterocycles as scd inhibitors |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| SG190667A1 (en) | 2008-05-23 | 2013-06-28 | Panmira Pharmaceuticals Llc | 5-lipoxygenase-activating protein inhibitor |
| US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
| ATE552255T1 (de) | 2008-06-05 | 2012-04-15 | Glaxo Group Ltd | 4-aminoindazole |
| KR101036913B1 (ko) * | 2008-12-26 | 2011-05-25 | 주식회사 포스코 | 고로의 머드건과 노즐팁 사이의 틈새 메움용 장치 및 방법 |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
| JP2012520686A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| JP2012521763A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EA201171175A1 (ru) | 2009-03-27 | 2012-05-30 | Мерк Шарп Энд Домэ Корп. | Опосредованное phk-интерференцией ингибирование экспрессии гена межклеточной адгезионной молекулы 1 (icam-1) с использованием короткой интерферирующей нуклеиновой кислоты (sihk) |
| JP2012521762A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US20100273744A1 (en) | 2009-04-24 | 2010-10-28 | Paul Martin Gore | Compounds |
| WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| JO3025B1 (ar) | 2009-04-30 | 2016-09-05 | Glaxo Group Ltd | الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3 |
| US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
| JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
| US20120245171A1 (en) | 2009-12-03 | 2012-09-27 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of pi3 kinases |
| US20120272951A1 (en) | 2009-12-16 | 2012-11-01 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| JP5876051B2 (ja) | 2010-09-08 | 2016-03-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体 |
| EP2614058B1 (en) | 2010-09-08 | 2015-07-08 | GlaxoSmithKline Intellectual Property Development Limited | POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| EP2630126B1 (en) | 2010-10-21 | 2015-01-07 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
| JP2013544794A (ja) | 2010-10-21 | 2013-12-19 | グラクソ グループ リミテッド | アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物 |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| CN104203231A (zh) | 2011-12-01 | 2014-12-10 | 葛兰素集团有限公司 | 治疗和预防眼疾病的方法 |
| CA2920059A1 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
| US9403801B2 (en) | 2014-03-28 | 2016-08-02 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| CA2948441A1 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| FR3022142B1 (fr) | 2014-06-16 | 2019-07-12 | Universite Paul Sabatier - Toulouse Iii | Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate |
| EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
| EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
| WO2019143874A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| CA3173172A1 (en) | 2020-03-26 | 2021-09-30 | Christopher D. Kane | Cathepsin inhibitors for preventing or treating viral infections |
| CN118852047B (zh) * | 2024-07-09 | 2025-09-16 | 吉林修正药业新药开发有限公司 | 一种枸橼酸莫沙必利中间体制备方法和枸橼酸莫沙必利制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870074A (en) * | 1986-04-30 | 1989-09-26 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, for enhancing gastrointestinal motility |
| JPS63264467A (ja) * | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体 |
| JPH01117882A (ja) | 1987-10-30 | 1989-05-10 | Dainippon Pharmaceut Co Ltd | 複素環式カルボン酸アミド誘導体 |
| JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
| JPH04247074A (ja) * | 1991-02-01 | 1992-09-03 | Yoshitomi Pharmaceut Ind Ltd | ４−モルホリノ安息香酸誘導体の製造法 |
| EP0760362B1 (en) | 1994-05-18 | 2002-08-14 | Nisshin Seifun Group Inc. | diaminomethylidene derivative |
| DE69511086T2 (de) * | 1994-05-18 | 2000-01-05 | Nisshin Flour Milling Co., Ltd. | Pyrimidinderivate |
| PT827500E (pt) | 1995-05-23 | 2002-04-29 | Janssen Pharmaceutica Nv | Derivados de (2-morfolinilmetil)benzamida |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19624704A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| CA2329777A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
| WO2000004003A1 (en) | 1998-07-14 | 2000-01-27 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027800A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| ES2230899T3 (es) | 1998-11-17 | 2005-05-01 | F. Hoffmann-La Roche Ag | Antagonistas iii receptores de 4-aroil-piperidin-ccr-3. |
| EP1131290B1 (en) | 1998-11-20 | 2008-02-20 | F. Hoffmann-La Roche Ag | Piperidine ccr-3 receptor antagonists |
| WO2000031032A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives-ccr-3 receptor antagonists |
| WO2000034278A1 (en) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient |
| CA2346933A1 (en) | 1998-12-18 | 2000-06-22 | Dupont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1140834A1 (en) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
| CA2347769A1 (en) | 1998-12-18 | 2000-06-22 | Dean A. Wacker | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
| CA2348923A1 (en) | 1998-12-18 | 2000-06-22 | Dean A. Wacker | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2347909A1 (en) | 1998-12-18 | 2000-06-22 | Joseph B. Santella, Iii | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| IL142768A0 (en) | 1998-12-18 | 2002-03-10 | Du Pont Pharm Co | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1140086A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
| WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000051608A1 (en) | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
| US6362201B1 (en) | 1999-03-02 | 2002-03-26 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
| WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000053600A1 (en) | 1999-03-11 | 2000-09-14 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| WO2000071518A2 (en) * | 1999-05-25 | 2000-11-30 | Sepracor, Inc. | Heterocyclic analgesic compounds and their use |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| BR0114323A (pt) * | 2000-09-29 | 2003-07-01 | Glaxo Group Ltd | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto |
-
2001
- 2001-09-28 BR BR0114323-9A patent/BR0114323A/pt not_active IP Right Cessation
- 2001-09-28 MX MXPA03002814A patent/MXPA03002814A/es unknown
- 2001-09-28 PL PL01362711A patent/PL362711A1/xx not_active Application Discontinuation
- 2001-09-28 ES ES01970023.6T patent/ES2527688T3/es not_active Expired - Lifetime
- 2001-09-28 US US10/381,767 patent/US7101882B2/en not_active Expired - Lifetime
- 2001-09-28 CA CA002423251A patent/CA2423251A1/en not_active Abandoned
- 2001-09-28 IL IL15509301A patent/IL155093A0/xx unknown
- 2001-09-28 AU AU2001290143A patent/AU2001290143A1/en not_active Abandoned
- 2001-09-28 JP JP2002531106A patent/JP5089846B2/ja not_active Expired - Lifetime
- 2001-09-28 KR KR10-2003-7004594A patent/KR20030031198A/ko not_active Withdrawn
- 2001-09-28 WO PCT/GB2001/004345 patent/WO2002026722A1/en not_active Ceased
- 2001-09-28 EP EP01970023.6A patent/EP1324990B1/en not_active Expired - Lifetime
- 2001-09-28 CN CNA018196365A patent/CN1678594A/zh active Pending
- 2001-09-28 CZ CZ20031195A patent/CZ20031195A3/cs unknown
- 2001-09-28 AR ARP010104602A patent/AR035205A1/es not_active Application Discontinuation
- 2001-09-28 NZ NZ525056A patent/NZ525056A/en unknown
- 2001-09-28 HU HU0302302A patent/HUP0302302A2/hu unknown
-
2003
- 2003-03-27 US US10/509,519 patent/US20050222147A1/en not_active Abandoned
- 2003-03-28 NO NO20031442A patent/NO20031442L/no unknown
-
2005
- 2005-11-22 US US11/284,544 patent/US7560548B2/en not_active Expired - Lifetime
-
2009
- 2009-02-24 US US12/391,855 patent/US20090163495A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004509952A5 (cg-RX-API-DMAC7.html) | ||
| JP2004509953A5 (cg-RX-API-DMAC7.html) | ||
| RU2011116232A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| RU2489426C2 (ru) | Производные аминопиразола | |
| JP2017538750A5 (cg-RX-API-DMAC7.html) | ||
| RU2349589C2 (ru) | 5-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,1-ДИОКСО-1,2,5-ТИАЗОЛИДИН-3-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ РТРазы 1В | |
| AU743489B2 (en) | 1,3,4-thiadiazoles useful for the treatment of CMV infections | |
| JP2013516415A5 (cg-RX-API-DMAC7.html) | ||
| RU2017125520A (ru) | Соединения, ингибирующие parg | |
| DE1283831T1 (de) | Inhibitoren der 11-beta-hydroxy-steroid-dehydrogenase des typs 1 | |
| JP2003534336A5 (cg-RX-API-DMAC7.html) | ||
| RU2009149696A (ru) | 5-замещенные индазолы в качестве ингибиторов киназы | |
| JP2006526656A5 (cg-RX-API-DMAC7.html) | ||
| JP2009502948A5 (cg-RX-API-DMAC7.html) | ||
| JP2019516737A5 (cg-RX-API-DMAC7.html) | ||
| RU2006130683A (ru) | Производные 3-замещенного 1, 5-дифенилпиразола, полезные в качестве св1 модуляторов | |
| RU2453544C3 (ru) | Фунгицидные азоциклические амиды | |
| RU2005109561A (ru) | Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции | |
| RU2006145205A (ru) | Терапевтические соединения: пиридин в качестве каркаса | |
| JPWO2020092196A5 (cg-RX-API-DMAC7.html) | ||
| RU2018112749A (ru) | Модуляторы индоламин-2,3-диоксигеназы | |
| RU2006125446A (ru) | Производные n-замещенного n-сульфониламиноциклопропана и их фармацевтическое применение | |
| JP2010540462A5 (cg-RX-API-DMAC7.html) | ||
| JP2016523963A5 (cg-RX-API-DMAC7.html) | ||
| JP2011500679A5 (cg-RX-API-DMAC7.html) |